arrow-left-endarrow-right-end

News & Updates

The Latest on Internet Pharmacies, Supplements, Designer Drugs,
and Other High-Risk Merchants

Filter By:

CBD Confusion in Iowa Highlights the Difficulty in Navigating Local CBD Laws

The Iowa Attorney General’s Office recently reminded Iowans that cannabidiol (CBD) is still considered a controlled substance in the state despite the newly passed Iowa Hemp Act, which legalized the production of hemp containing less than 0.3% THC. The confusion has resulted in enforcement efforts to stop its sale, and it illustrates a larger legal…

Continue Reading ›

The Top Marketing Claims CBD Merchants and Manufacturers Should Avoid

One of the aspects of cannabidiol (CBD) sales that can attract regulatory scrutiny is the way in which merchants market their CBD products. In the past five years, the FDA has sent many warning letters to manufacturers and merchants of CBD products for claims that their products can prevent, cure, mitigate, or treat diseases. No…

Continue Reading ›

LegitScript Announces New CBD Certification Program

We’re happy to announce a new certification program for legally compliant CBD products and websites. Starting today, US manufacturers and merchants can apply through LegitScript to certify CBD products and websites that are in compliance with USDA, FDA, FTC, and DEA regulations, as well as state-specific laws. LegitScript is the global leader in merchant and…

Continue Reading ›

The Rising Threat of Unwashed Poppy Seeds

As e-commerce platforms, payment service providers, and regulatory agencies crack down on illicit opioid sales on the internet, many consumers are turning to alternative products, either to replicate the effects of opioids or to aid in opioid withdrawal. Many of these products, however, are unregulated, illegal, and potentially dangerous. LegitScript analysts have recently identified a…

Continue Reading ›

Three Things Payment Service Providers Need to Know About CBD Sales

The 2018 Farm Bill, which was signed into law last month, includes provisions removing hemp and its extracts, including hemp-derived cannabidiol (CBD), from the DEA’s Controlled Substances schedules entirely. This is a monumental shift for industrial hemp and CBD in the US, and it promises big opportunities for CBD merchants and the payment facilitators that…

Continue Reading ›